Laboratory Monitoring of High-Dose Factor VIIa Therapy [2]

Annals of Internal Medicine

Volumn 139, Issue 9, 2003, Pages 791-

  Hoffman, Maureane ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTICOAGULATION; BLEEDING; DOSE RESPONSE; DRUG EFFECT; DRUG LABELING; HEMOPHILIA; HUMAN; LETTER; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 1642502375     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-139-9-200311040-00020     Document Type: Letter

References (5)

1. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 2002;137:884-8. [PMID: 12458988]
2. Hoffman M, Monroe DM 3rd. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol. 2001;38:6-9. [PMID: 11735103]
3. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542-7. [PMID: 9401063]
4. Gerotziafas GT, Zervas K, Arzoglou P, Karavaggeli E, Parashou S, Van Dreden P, et al. On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation. Br J Haematol. 2002;117:705-8. [PMID: 12028045]
5. Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res. 1989;56:603-9. [PMID: 2626745]